Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimosiamose in ozone-induced airway inflammation
NCT00962481Phase 2Completed
- Sponsor
- Revotar Biopharmaceuticals
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Bimosiamose with Placebo (2 arms). Primary endpoint: Absolute number of sputum neutrophils at Day 4. Status: completed.
02
Drugs
bimosiamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00962481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962481.